Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast

International Surgery

Volumn 93, Issue 3, 2008, Pages 163-168

  Yagmurdur, M C ^a   Atac, F B ^a   Tutar, N U ^a   Verdi, H ^a   Isiklar, I ^a   Ozdemir, B H ^a   Ozbek, N ^a   Karakayali, H ^a   Haberal, Mehmet ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Breast preserving surgery; Invasive ductal carcinoma of the breast; PAI 1 genotype; Partial mastectomy + axilla dissection

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ALLELE; ARTICLE; BREAST TUMOR; CANCER INVASION; DISEASE FREE SURVIVAL; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; NONPARAMETRIC TEST; PAGET NIPPLE DISEASE; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR RECURRENCE; TURKEY (REPUBLIC);

ALLELES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TURKEY;

EID: 51149095014     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Landis SH, Murray T, Bolden S. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36
2. Mettlin C. Global breast cancer mortality statistics. CA Cancer J Clin 1999;49:138-144
3. Clark GM. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 1994;30:117-126
4. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early stage breast cancer. Oncologist 2004;9:606-616
5. Borgfeldt C, Casslen B, Liu CL, Hansson S, Lecander I, Astedt B. High tissue content of urokinase plasminogen activator (u-PA) associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer 1998;79:588-595
6. Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer 2000;10:372-381
7. Janicke F, Schimitt M, Graeff H. Clinical relevance of the urokinase type and tissue type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991;17:303-312
8. Kwaan HC, Wang J, Svoboda K, Decklerk PJ. Plasminogen activator inhibitor 1 may promote tumor growth through inhibition of apoptosis. Br J Cancer 2000;82:1702-1708
9. Akar N, Yilmaz E, Akar E, Avcu F, Yalcin A, Cin S. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A. Thromb Res 2000;15;97:227- 230
10. Miller SA, Dykes DD, Polesky HS. Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215
11. Kruithof EKO, Maker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86:4007-4024
12. Deng C, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-1571
13. Rudoph-Owen LA, Chan R, Muller WJ, Matrisian LM. The matrix metalloproteinase matrilysin influences early stage mammary tumorigenesis. Cancer Res 1998;58:5500-5506
14. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Current Pharm Des 2004;10:39-49
15. Loktionov A, Watson MA, Stebbings WSL, Speakman CTL, Bingham SA. Plasminogen activator inhibitor gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett 2003;189:189-196
16. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744
17. Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brunner N, Harbeck N et al. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 2004;64:4563-4568
18. Borgfeldt C, Hansson SR, Gustavsson B, Masback A, Casslen B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer 2001;92:497-502
19. Whitley BR, Palmieri D, Twerdi CD, Church FC. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 2004;296:151-162
20. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990;16:127-133
21. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992; 339:1-15
22. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998;52:227-237
23. Schlechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI et al. The neu oncogene: an erb-B-related gene encoding a 185 000-Mr rumour antigen. Nature 1984;312:513-516
24. Sheldon DG. Beyond lymph node staging: molecular predictors of outcome in breast cancer. Surg Oncol Clin North Am 2005;14:69-84
25. 0 patients with long-term follow-up. J Clin Oncol 1993;11:2090-2100
26. Woo CS, Silberman H, Nakamura SK, Ye W, Sposto R, Colburn W et al. Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. Am J Surg 2002;184:337-340
27. Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5:737-745
28. Lauria R, Perrone F, Carlomagno C. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995;76:1772-1778
29. Castello R, Espana F, Vazquez C, Fuster C, Almenar SM, Aznar J et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res 2006;117: 487-489
30. Zhang X, Shu XO, Cai Q, Ruan Z, Gao YT, Zheng W. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival. Clin Cancer Res 2006;12:6037-6042